Your FDA at work: Killing the demented at $56,000/year

Part of the Great Reset or the Build Back Better and Younger program? By Meryl Nass, MD | November 24, 2021 You probably recall that nearly a year ago an FDA advisory committee voted almost unanimously not to license the new drug Aduhelm for Alzheimer’s dementia. Then FDA, with Janet Woodcock at its helm, gave the drug […]